Meeting unmet medical needs - important preclinical results supporting the benefit of AT2 receptor agonism

 

  • The restoration of heart function after myocardial infarction, and the acceleration of remodeling as prevention of heart failure are both still acute medical needs. Vicore Pharma's candidate drug, C21, has shown excellent capability in enhancing the repair of damaged tissue, and rapid restoration of heart function has been established in preclinical models. Furthermore, various models have seen our lead compound demonstrate impressive results on the kidney, brain and eye damage caused by hypertension and diabetes.
  • Glucocorticoids are a well-established group of anti-inflammatory drugs. However, they are in some cases accompanied by severe side effects, particularly when a high dosage extends over long periods of time. There is a great demand for alternative and effective anti-inflammatory drugs with fewer side effects. Vicore Pharma's preclinical data strongly suggests that the company's technology could fill this important gap, as stimulation of the AT2 receptor with C21 has demonstrated potent anti-inflammatory capability for a variety of clinical indication areas, e.g. scleroderma, multiple sclerosis and cardiovascular disease.
  • The neoroprotective and neuroregenerative properties of C21 have shown promising results in models of neural damage such as is caused by spinal cord injury and stroke.